New findings illustrate pathway for screening high-risk individuals for pancreatic cancer
An international collaboration of scientists and healthcare professionals is developing a promising surveillance...
A new hope for men with metastatic prostate cancer
MUHC patients are the first enrolled in a new global Phase 1 clinical trial testing Actinium-225, a therapeutic agent used in nuclear precision medicine
An opportunity to learn, celebrate and connect during Black History Month at the RI-MUHC
An expert panel explored Equity, Diversity and Inclusion in research and healthcare
Outstanding early-career researcher at the RI-MUHC named Terry Fox New Investigator
Joanna Przybyl receives one of seven 2024 Terry Fox New Investigator awards for her work in osteosarcoma
Results of seed funding competition in precision oncology
The RI-MUHC’s Cancer Research Program is pleased to announce the winners of Precision Oncology Hypothesis-Driven Seed Funding Competition
$3 million for FRQS Dual Chairs in Artificial Intelligence and Health co-led by RI-MUHC researchers
The FRQS Dual AI Chairs Program supports research collaborations across disciplines in pursuit of the significant...
Triple-negative breast cancer: a new clinical study opens new and promising therapeutic prospects
The RI-MUHC will host a new Phase 3 randomized clinical trial called TROPION-Breast04, as announced today...
The 2023 RI-MUHC Annual Report is online!
An invitation from Dr. Rhian Touyz
Cutting-edge facilities and expertise on display at the 2023 Platform Expo
Researchers and trainees learn from the experts in an interactive half-day event
Seeking to understand how cancer spreads
A new RI-MUHC research study identifies the role of neutrophil extracellular traps in promoting cancer metastasis to the lymph nodes